Correction: Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposure

Key Points

To correct the previous findings related to the pharmacokinetics of pyrazinamide in tuberculosis treatment affected by diabetes mellitus.
Correction of previous data and analysis regarding the interethnic cohort study.
Re-evaluation of drug exposure metrics influenced by diabetes mellitus.
Comparison of pharmacokinetic parameters across different ethnic groups.
Validation of earlier findings on the effect of diabetes on pyrazinamide levels.
Identification of significant interethnic variations in drug exposure.
Proposed adjustments for optimizing tuberculosis treatment protocols.

We only have this paper's title and publication details.

This correction outlines findings on pyrazinamide drug exposure in tuberculosis patients with diabetes mellitus, implying optimization strategies.

No takes yet. Share an insight, caveat, or question.

Jayanti et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share